Freeline Therapeutics Holdings Plc

NASDAQ FRLN

Data sourced from

and

Daily

Download Data

Freeline Therapeutics Holdings Plc Enterprise Value to EBITDA (EV/EBITDA) on February 29, 2024

Freeline Therapeutics Holdings Plc Enterprise Value to EBITDA (EV/EBITDA) is NA on February 29, 2024, a NA change year over year. The EV/EBITDA ratio compares a company's enterprise value to its EBITDA. It provides insight into the company's valuation relative to its earnings and is commonly used in comparing the relative value of different companies within an industry. A lower ratio suggests a potentially more favorable valuation.

Freeline Therapeutics Holdings Plc 52-week high Enterprise Value to EBITDA (EV/EBITDA) is NA on February 29, 2024, which is NA below the current Enterprise Value to EBITDA (EV/EBITDA).
Freeline Therapeutics Holdings Plc 52-week low Enterprise Value to EBITDA (EV/EBITDA) is NA on February 29, 2024, which is NA below the current Enterprise Value to EBITDA (EV/EBITDA).
Freeline Therapeutics Holdings Plc average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is NA.

NASDAQ: FRLN

Freeline Therapeutics Holdings Plc

CEO	Mr. Michael J. Parini J.D.
IPO Date	Aug. 7, 2020
Location	United Kingdom
Headquarters	Stevenage Bioscience Catalyst, Stevenage, United Kingdom, SG1 2FX
Employees	152
Sector	Healthcare
Industry	Biotechnology

Description

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Key trends